Edgestream Partners L.P. Purchases New Holdings in TG Therapeutics, Inc. (NASDAQ:TGTX)

Edgestream Partners L.P. purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 53,738 shares of the biopharmaceutical company's stock, valued at approximately $1,618,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Arizona State Retirement System grew its holdings in shares of TG Therapeutics by 0.9% during the fourth quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock valued at $1,283,000 after buying an additional 364 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 371 shares in the last quarter. Brookstone Capital Management boosted its position in TG Therapeutics by 3.7% during the fourth quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock valued at $527,000 after purchasing an additional 624 shares during the last quarter. Daymark Wealth Partners LLC boosted its position in TG Therapeutics by 1.7% during the fourth quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock valued at $1,249,000 after purchasing an additional 689 shares during the last quarter. Finally, New York State Teachers Retirement System boosted its position in TG Therapeutics by 1.9% during the fourth quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company's stock valued at $1,317,000 after purchasing an additional 837 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.

Remove Ads

Insider Buying and Selling

In related news, CFO Sean A. Power sold 10,021 shares of the business's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now owns 660,611 shares of the company's stock, valued at approximately $18,847,231.83. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.50% of the stock is owned by insiders.

TG Therapeutics Stock Down 0.5 %

Shares of NASDAQ:TGTX traded down $0.17 on Thursday, reaching $37.06. The company had a trading volume of 4,302,244 shares, compared to its average volume of 2,670,921. TG Therapeutics, Inc. has a twelve month low of $12.93 and a twelve month high of $40.31. The stock has a 50-day moving average price of $31.52 and a 200 day moving average price of $28.83. The stock has a market capitalization of $5.82 billion, a P/E ratio of -370.56 and a beta of 2.30. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $108.19 million during the quarter, compared to analysts' expectations of $100.67 million. On average, equities analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analysts Set New Price Targets

TGTX has been the subject of a number of research reports. JPMorgan Chase & Co. lifted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a research report on Monday, November 25th. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Finally, HC Wainwright reissued a "buy" rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.